Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Psilocybin adjunctive therapy for treatment-resistant depression
2018-002577-22Phase 2Completed
- Sponsor
- COMPASS Pathways
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of psilocybin in treatment-resistant depression (TRD) and major depressive disorder (MDD), sponsored by COMPASS Pathways. Primary endpoint: Change in MADRS total score from baseline to Week 3. Started Oct 2019; status: completed.
02
Drugs
psilocybin
03
Conditions
treatment-resistant depression (TRD)major depressive disorder (MDD)
Beyond the preview
Go deeper on 2018-002577-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002577-22.